Dr. Dicato on Agents to Treat Thrombocytopenia for Patients With Cancer

Video

Mario Dicato, MD, Hematology-Oncology Service, Centre Hospitalier de Luxembourg, discusses 3 agents used for the treatment or reduction of thrombocytopenia for patients with cancer.

Mario Dicato, MD, Hematology-Oncology Service, Centre Hospitalier de Luxembourg, discusses 3 agents used for the treatment or reduction of thrombocytopenia for patients with cancer.

Rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa) are currently available for patients, Dicato explains. However, these agents have been criticized due to a lack of data demonstrating efficacy and safety.

An advantage is that patients do not need to undergo platelet testing after receiving these oral treatments, he adds.

Related Videos
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Ashwin Kishtagari, MD
Somedeb Ball, MBBS